1160 related articles for article (PubMed ID: 28801166)
1. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
[TBL] [Abstract][Full Text] [Related]
2. Development of a Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay for the Inhibition of Keap1-Nrf2 Protein-Protein Interaction.
Lee S; Abed DA; Beamer LJ; Hu L
SLAS Discov; 2021 Jan; 26(1):100-112. PubMed ID: 32564647
[TBL] [Abstract][Full Text] [Related]
3. Characterization of novel small-molecule NRF2 activators: Structural and biochemical validation of stereospecific KEAP1 binding.
Huerta C; Jiang X; Trevino I; Bender CF; Ferguson DA; Probst B; Swinger KK; Stoll VS; Thomas PJ; Dulubova I; Visnick M; Wigley WC
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2537-2552. PubMed ID: 27474998
[TBL] [Abstract][Full Text] [Related]
4. Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.
Davies TG; Wixted WE; Coyle JE; Griffiths-Jones C; Hearn K; McMenamin R; Norton D; Rich SJ; Richardson C; Saxty G; Willems HM; Woolford AJ; Cottom JE; Kou JP; Yonchuk JG; Feldser HG; Sanchez Y; Foley JP; Bolognese BJ; Logan G; Podolin PL; Yan H; Callahan JF; Heightman TD; Kerns JK
J Med Chem; 2016 Apr; 59(8):3991-4006. PubMed ID: 27031670
[TBL] [Abstract][Full Text] [Related]
5. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
Pallesen JS; Tran KT; Bach A
J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
[TBL] [Abstract][Full Text] [Related]
6. Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds.
Pallesen JS; Narayanan D; Tran KT; Solbak SMØ; Marseglia G; Sørensen LME; Høj LJ; Munafò F; Carmona RMC; Garcia AD; Desu HL; Brambilla R; Johansen TN; Popowicz GM; Sattler M; Gajhede M; Bach A
J Med Chem; 2021 Apr; 64(8):4623-4661. PubMed ID: 33818106
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Keap1-Nrf2 small-molecule inhibitors from phytochemicals based on molecular docking.
Li M; Huang W; Jie F; Wang M; Zhong Y; Chen Q; Lu B
Food Chem Toxicol; 2019 Nov; 133():110758. PubMed ID: 31412289
[TBL] [Abstract][Full Text] [Related]
8. NRF2 activation by reversible KEAP1 binding induces the antioxidant response in primary neurons and astrocytes of a Huntington's disease mouse model.
Moretti D; Tambone S; Cerretani M; Fezzardi P; Missineo A; Sherman LT; Munoz-Sajuan I; Harper S; Dominquez C; Pacifici R; Tomei L; Park L; Bresciani A
Free Radic Biol Med; 2021 Jan; 162():243-254. PubMed ID: 33096251
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis.
Jiang ZY; Lu MC; Xu LL; Yang TT; Xi MY; Xu XL; Guo XK; Zhang XJ; You QD; Sun HP
J Med Chem; 2014 Mar; 57(6):2736-45. PubMed ID: 24512214
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Binding Energy of Keap1 Interaction Motifs in the Nrf2 Antioxidant Pathway and Design of Potential High-Affinity Peptides.
Karttunen M; Choy WY; Cino EA
J Phys Chem B; 2018 Jun; 122(22):5851-5859. PubMed ID: 29745220
[TBL] [Abstract][Full Text] [Related]
11. Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions.
Jiang ZY; Lu MC; You QD
J Med Chem; 2016 Dec; 59(24):10837-10858. PubMed ID: 27690435
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency.
Lu MC; Jiao Q; Liu T; Tan SJ; Zhou HS; You QD; Jiang ZY
Eur J Med Chem; 2018 Jan; 143():1578-1589. PubMed ID: 29117896
[TBL] [Abstract][Full Text] [Related]
13. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors.
Mou Y; Wen S; Li YX; Gao XX; Zhang X; Jiang ZY
Eur J Med Chem; 2020 Sep; 202():112532. PubMed ID: 32668381
[TBL] [Abstract][Full Text] [Related]
14. Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1.
Unni S; Deshmukh P; Krishnappa G; Kommu P; Padmanabhan B
FEBS J; 2021 Mar; 288(5):1599-1613. PubMed ID: 32672401
[TBL] [Abstract][Full Text] [Related]
15. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
[TBL] [Abstract][Full Text] [Related]
16. Replacement of a Naphthalene Scaffold in Kelch-like ECH-Associated Protein 1 (KEAP1)/Nuclear Factor (Erythroid-derived 2)-like 2 (NRF2) Inhibitors.
Richardson BG; Jain AD; Potteti HR; Lazzara PR; David BP; Tamatam CR; Choma E; Skowron K; Dye K; Siddiqui Z; Wang YT; Krunic A; Reddy SP; Moore TW
J Med Chem; 2018 Sep; 61(17):8029-8047. PubMed ID: 30122040
[TBL] [Abstract][Full Text] [Related]
17. Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson's disease animal model.
Kim S; Indu Viswanath AN; Park JH; Lee HE; Park AY; Choi JW; Kim HJ; Londhe AM; Jang BK; Lee J; Hwang H; Lim SM; Pae AN; Park KD
Neuropharmacology; 2020 May; 167():107989. PubMed ID: 32032607
[TBL] [Abstract][Full Text] [Related]
18. Structural and mechanistic insights into the Keap1-Nrf2 system as a route to drug discovery.
Madden SK; Itzhaki LS
Biochim Biophys Acta Proteins Proteom; 2020 Jul; 1868(7):140405. PubMed ID: 32120017
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions.
Lu MC; Shao HL; Liu T; You QD; Jiang ZY
Eur J Med Chem; 2020 Dec; 207():112734. PubMed ID: 32866756
[TBL] [Abstract][Full Text] [Related]
20. Direct Keap1-kelch inhibitors as potential drug candidates for oxidative stress-orchestrated diseases: A review on In silico perspective.
Boyenle ID; Divine UC; Adeyemi R; Ayinde KS; Olaoba OT; Apu C; Du L; Lu Q; Yin X; Adelusi TI
Pharmacol Res; 2021 May; 167():105577. PubMed ID: 33774182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
